We are live on ! Find out more
BBLGW

Bone Biologics Corp Warrants
BBLGW

2 hedge funds and large institutions have $1.82M invested in Bone Biologics Corp Warrants in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.82% less ownership

Funds ownership: 3.6% → 2.79% (-0.82%)

10% less capital invested

Capital invested by funds: $2.02M → $1.82M (-$203K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$2.68K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$603
2
Bank of America
Bank of America
North Carolina
-$78

BBLGW Hedge Fund Activity: Q3 2024 in Review

2 of the 6,981 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q3 2024, worth a combined $1.82M — down 10% from $2.02M a quarter earlier.

Fund positioning in BBLGW was balanced in Q3 2024: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $2.68K. The largest seller was Citadel Advisors, cutting an estimated $603.

  • 2 institutional investors held Bone Biologics Corp Warrants (BBLGW) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $1.82M of Bone Biologics Corp Warrants stock for Q3 2024, down 10% quarter-over-quarter.
  • 1 fund opened new Bone Biologics Corp Warrants positions in Q3 2024 and 1 closed out, a net change of 0 holders.
  • The largest Bone Biologics Corp Warrants buyer in Q3 2024 was UBS Group, an estimated $2.68K added.
  • The largest Bone Biologics Corp Warrants seller in Q3 2024 was Citadel Advisors, an estimated $603 sold.

Based on aggregated 13F filings for Q3 2024.